Baseline characteristics of the study cohort (n = 672)
| Variable . | n (% missing) . | Median [IQR] or count (%) . |
|---|---|---|
| Demographics and clinical characteristics | ||
| Age (y) | 672 (0) | 64 [54-72] |
| Female | 672 (0) | 260 (38.7) |
| BMI (kg/m2) | 545 (18.9) | 24.4 [21.5-28.0] |
| ECOG | 553 (17.7) | 0 [0-1] |
| 0-1 | — | 511 (92.4) |
| ≥2 | — | 42 (7.6) |
| Charlson comorbidity index | 672 (0) | 8 [7-9] |
| History of VTE* | 672 (0) | 85 (12.6) |
| History of VTE during current cancer disease | 672 (0) | 65 (8.0) |
| History of ATE* | 672 (0) | 62 (9.2) |
| History of ATE during current cancer disease | 672 (0) | 15 (2.2) |
| Continuous anticoagulation | 672 (0) | 111 (16.5) |
| Continuous antiplatelet therapy | 672 (0) | 133 (19.8) |
| Tumor specifics at inclusion | ||
| Tumor type | 672 (0) | — |
| Melanoma | — | 204 (30.4) |
| Non-small cell lung cancer | — | 162 (24.1) |
| Renal cell carcinoma | — | 74 (11.0) |
| Head and neck squamous cell carcinoma | — | 70 (10.4) |
| Urothelial | — | 33 (4.9) |
| Lymphoma/myeloma | — | 28 (4.2) |
| Hepatocellular cancer | — | 20 (3.0) |
| Gynecological | — | 18 (2.7) |
| Sarcoma | — | 17 (2.5) |
| Colorectal cancer | — | 11 (1.6) |
| Other† | — | 35 (5.2) |
| Stage | 660 (1.8) | — |
| I | — | 3 (0.5) |
| II | — | 13 (2.0) |
| III | — | 78 (11.8) |
| IV | — | 566 (85.8) |
| PD-L1 (TPS) | 178 (73.5) | 10 [0-60] |
| PD-L1 negative | — | 58 (32.6) |
| Therapeutic management | ||
| Immune checkpoint inhibitor agent | 672 (0) | — |
| Nivolumab | — | 282 (42.0) |
| Pembrolizumab | — | 269 (40.0) |
| Ipilimumab | — | 45 (6.7) |
| Atezolizumab | — | 30 (4.5) |
| Avelumab | — | 6 (0.9) |
| Ipilimumab + nivolumab | — | 40 (6.0) |
| Therapy cycles | — | 7 [4-18], range: 1-128 |
| Treatment intent | — | — |
| (Pseudo-)neoadjuvant | — | 1 (0.1) |
| (Pseudo-)adjuvant | — | 19 (2.8) |
| Palliative | — | 651 (96.9) |
| Line of anticancer therapy | — | 2 [1-2], range: 1-7 |
| Prior chemotherapy | — | 377 (56.1) |
| Prior radiotherapy | — | 320 (47.6) |
| Prior removal of primary tumor | — | 357 (53.1) |
| Concomitant therapy during immune checkpoint inhibitor therapy | — | — |
| Chemotherapy | — | 43 (6.4) |
| Targeted therapy | — | 69 (10.3) |
| Radiotherapy | — | 107 (15.9) |
| Surgery | — | 43 (6.4) |
| Medical anticancer therapy after immune checkpoint inhibitor therapy | — | 210 (31.3) |
| Variable . | n (% missing) . | Median [IQR] or count (%) . |
|---|---|---|
| Demographics and clinical characteristics | ||
| Age (y) | 672 (0) | 64 [54-72] |
| Female | 672 (0) | 260 (38.7) |
| BMI (kg/m2) | 545 (18.9) | 24.4 [21.5-28.0] |
| ECOG | 553 (17.7) | 0 [0-1] |
| 0-1 | — | 511 (92.4) |
| ≥2 | — | 42 (7.6) |
| Charlson comorbidity index | 672 (0) | 8 [7-9] |
| History of VTE* | 672 (0) | 85 (12.6) |
| History of VTE during current cancer disease | 672 (0) | 65 (8.0) |
| History of ATE* | 672 (0) | 62 (9.2) |
| History of ATE during current cancer disease | 672 (0) | 15 (2.2) |
| Continuous anticoagulation | 672 (0) | 111 (16.5) |
| Continuous antiplatelet therapy | 672 (0) | 133 (19.8) |
| Tumor specifics at inclusion | ||
| Tumor type | 672 (0) | — |
| Melanoma | — | 204 (30.4) |
| Non-small cell lung cancer | — | 162 (24.1) |
| Renal cell carcinoma | — | 74 (11.0) |
| Head and neck squamous cell carcinoma | — | 70 (10.4) |
| Urothelial | — | 33 (4.9) |
| Lymphoma/myeloma | — | 28 (4.2) |
| Hepatocellular cancer | — | 20 (3.0) |
| Gynecological | — | 18 (2.7) |
| Sarcoma | — | 17 (2.5) |
| Colorectal cancer | — | 11 (1.6) |
| Other† | — | 35 (5.2) |
| Stage | 660 (1.8) | — |
| I | — | 3 (0.5) |
| II | — | 13 (2.0) |
| III | — | 78 (11.8) |
| IV | — | 566 (85.8) |
| PD-L1 (TPS) | 178 (73.5) | 10 [0-60] |
| PD-L1 negative | — | 58 (32.6) |
| Therapeutic management | ||
| Immune checkpoint inhibitor agent | 672 (0) | — |
| Nivolumab | — | 282 (42.0) |
| Pembrolizumab | — | 269 (40.0) |
| Ipilimumab | — | 45 (6.7) |
| Atezolizumab | — | 30 (4.5) |
| Avelumab | — | 6 (0.9) |
| Ipilimumab + nivolumab | — | 40 (6.0) |
| Therapy cycles | — | 7 [4-18], range: 1-128 |
| Treatment intent | — | — |
| (Pseudo-)neoadjuvant | — | 1 (0.1) |
| (Pseudo-)adjuvant | — | 19 (2.8) |
| Palliative | — | 651 (96.9) |
| Line of anticancer therapy | — | 2 [1-2], range: 1-7 |
| Prior chemotherapy | — | 377 (56.1) |
| Prior radiotherapy | — | 320 (47.6) |
| Prior removal of primary tumor | — | 357 (53.1) |
| Concomitant therapy during immune checkpoint inhibitor therapy | — | — |
| Chemotherapy | — | 43 (6.4) |
| Targeted therapy | — | 69 (10.3) |
| Radiotherapy | — | 107 (15.9) |
| Surgery | — | 43 (6.4) |
| Medical anticancer therapy after immune checkpoint inhibitor therapy | — | 210 (31.3) |
BMI, body mass index; MMR-d, mismatch repair deficiency; MSI, microsatellite instability; TPS, tumor proportion score.
History of VTE/ATE comprises all reported thrombotic events reported prior to the initiation of immune checkpoint inhibitors.
Includes prostate cancer (n = 8), Merkel cell carcinoma (n = 5), malignant pleural mesothelioma (n = 4), gastroesophageal cancer (n = 4), breast cancer (n = 4), small cell lung cancer (n = 3), cancer of unknown primary (n = 2), glioblastoma (n = 2), penile carcinoma (n = 1), glioma (n = 1), and thyroid carcinoma (n = 1).